CY1108714T1 - Ανταγωνιστες υποδοχεα cgrp - Google Patents

Ανταγωνιστες υποδοχεα cgrp

Info

Publication number
CY1108714T1
CY1108714T1 CY20091100053T CY091100053T CY1108714T1 CY 1108714 T1 CY1108714 T1 CY 1108714T1 CY 20091100053 T CY20091100053 T CY 20091100053T CY 091100053 T CY091100053 T CY 091100053T CY 1108714 T1 CY1108714 T1 CY 1108714T1
Authority
CY
Cyprus
Prior art keywords
cgrp
compounds
headaches
directed
formula
Prior art date
Application number
CY20091100053T
Other languages
English (en)
Inventor
Christopher S Burgey
Zhengwu J Deng
Diem N Nguyen
Daniel V Paone
Anthony W Shaw
Theresa M Williams
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of CY1108714T1 publication Critical patent/CY1108714T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση στρέφεται προς ενώσεις του χημικού τύπου (I) και του χημικού τύπου (Π) (όπου οι μεταβλητές R1, R2, R3, R4, Α, Β, G, J, Q, Τ, U, V, W, Χ και Υ είναι αυτές που ορίζονται στο παρόν) και οι οποίες χρησιμοποιούνται στην αγωγή ή πρόληψη των νοσημάτων στα οποία υπάρχει εμπλοκή του CGRP, όπως κεφαλαλγίες, ημικρανίες και αθροιστικές κεφαλαλγίες. Επίσης, η εφεύρεση στρέφεται προς φαρμακευτικές συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις και τη χρήση αυτών των ενώσεων και συνθέσεων για την πρόληψη ή την αγωγή των νοσημάτων που υπάρχει συμμετοχή του CGRP.
CY20091100053T 2003-04-15 2009-01-15 Ανταγωνιστες υποδοχεα cgrp CY1108714T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46308903P 2003-04-15 2003-04-15
US51035203P 2003-10-10 2003-10-10
EP04749887A EP1638969B1 (en) 2003-04-15 2004-04-09 Cgrp receptor antagonists

Publications (1)

Publication Number Publication Date
CY1108714T1 true CY1108714T1 (el) 2014-04-09

Family

ID=33303112

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100053T CY1108714T1 (el) 2003-04-15 2009-01-15 Ανταγωνιστες υποδοχεα cgrp

Country Status (33)

Country Link
US (6) US6953790B2 (el)
EP (2) EP2039694B1 (el)
JP (1) JP3967766B2 (el)
KR (1) KR100769030B1 (el)
CN (1) CN100384843C (el)
AR (1) AR045887A1 (el)
AT (1) ATE413400T1 (el)
AU (1) AU2004230926B2 (el)
BR (1) BRPI0409601A (el)
CA (1) CA2522220C (el)
CL (1) CL2004000788A1 (el)
CO (1) CO5640130A2 (el)
CY (1) CY1108714T1 (el)
DE (1) DE602004017608D1 (el)
DK (1) DK1638969T3 (el)
EC (1) ECSP056097A (el)
ES (1) ES2314417T3 (el)
HK (1) HK1090922A1 (el)
HR (1) HRP20080666T3 (el)
IS (1) IS2759B (el)
JO (1) JO2355B1 (el)
MA (1) MA27728A1 (el)
MX (1) MXPA05011166A (el)
NO (1) NO327655B1 (el)
NZ (1) NZ543357A (el)
PE (1) PE20050020A1 (el)
PL (1) PL1638969T3 (el)
PT (1) PT1638969E (el)
RU (1) RU2308458C2 (el)
SI (1) SI1638969T1 (el)
TW (1) TWI314931B (el)
UA (1) UA82877C2 (el)
WO (2) WO2004092168A1 (el)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
CA2487976C (en) * 2002-06-05 2011-07-26 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
ATE466860T1 (de) * 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
WO2005000807A2 (en) * 2003-06-26 2005-01-06 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
WO2005013894A2 (en) * 2003-06-26 2005-02-17 Merck & Co., Inc. Benzodiazepine cgrp receptor antagonists
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
EP1765805B1 (en) * 2004-01-29 2013-11-20 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CN101090885A (zh) * 2004-02-23 2007-12-19 塔夫茨大学信托人 作为构象限定的肽模拟物抑制剂的内酰胺类化合物
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
JP2008515895A (ja) * 2004-10-07 2008-05-15 メルク エンド カムパニー インコーポレーテッド Ｃｇｒｐ受容体拮抗薬
DE602005027870D1 (de) * 2004-10-14 2011-06-16 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
AU2005299852B2 (en) * 2004-10-22 2011-08-04 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2467060B (en) * 2005-02-11 2010-09-01 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB2423085C (en) * 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
ATE537170T1 (de) * 2005-03-14 2011-12-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
BRPI0618705B8 (pt) 2005-11-14 2021-05-25 Labrys Biologics Inc anticorpos antagonistas humanizados direcionados contra peptídeo relacionado ao gene da calcitonina, composição farmacêutica e uso dos mesmos
CN100371327C (zh) * 2005-11-17 2008-02-27 江苏工业学院 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
WO2007061677A2 (en) * 2005-11-18 2007-05-31 Merck & Co., Inc. Spirolactam aryl cgrp receptor antagonists
ES2330166T3 (es) 2006-04-10 2009-12-04 MERCK & CO., INC. Procedimiento de preparacion de un antagonista de cgrp.
WO2007120592A1 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Cgrp antagonist salt
ES2328186T3 (es) 2006-04-10 2009-11-10 MERCK & CO., INC. Procedimiento de preparacion de un intermedio de antagonista del cgrp de caprolactama.
CN101421267B (zh) * 2006-04-10 2011-10-19 默沙东公司 制备吡啶杂环cgrp拮抗剂中间体的方法
ATE517903T1 (de) * 2006-05-02 2011-08-15 Bristol Myers Squibb Co Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten.
US7470680B2 (en) * 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
CN101443323A (zh) * 2006-05-09 2009-05-27 默克公司 取代的螺环cgrp受体拮抗剂
US7834000B2 (en) * 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
ZA200810791B (en) * 2006-06-13 2010-03-31 Vertex Pharma CGRP receptor antagonists
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2007281468B2 (en) 2006-08-02 2012-12-06 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
WO2008030524A2 (en) * 2006-09-08 2008-03-13 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist
ATE540944T1 (de) 2007-05-23 2012-01-15 Merck Sharp & Dohme Pyridylpiperidinorexin-rezeptorantagonisten
GB0712392D0 (en) * 2007-06-26 2007-08-01 Glaxo Group Ltd Novel compounds
US20090075977A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk0974
CA2722536A1 (en) * 2008-02-05 2009-08-13 Merck & Co., Inc. Prodrugs of cgrp receptor antagonist
EP2254413A4 (en) * 2008-02-19 2011-10-26 Merck Sharp & Dohme IMIDAZOBENZAZEPIN-CGRP receptor antagonists
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
WO2010002763A1 (en) * 2008-06-30 2010-01-07 Merck & Co., Inc. Solid dosage formulations of telcagepant potassium
US8623863B2 (en) 2008-10-21 2014-01-07 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
IN2012DN02521A (el) 2009-08-28 2015-08-28 Rinat Neuroscience Corp
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI487706B (zh) 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
AU2012231293A1 (en) * 2011-03-18 2013-08-29 Merck Sharp & Dohme Corp. Piperidine carboxamide spirohydantoin CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
EP2709662B1 (en) 2011-05-20 2019-07-31 AlderBio Holdings LLC Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
BR112013029932A2 (pt) 2011-05-20 2017-01-31 Alderbio Holdings Llc composições anti-cgrp e usos das mesmas
CA2836800A1 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
CA2849213A1 (en) 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination of riluzole and ck-2017357 for treating als
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
HUE034936T2 (hu) 2012-02-27 2018-03-28 Bristol Myers Squibb Co N-(5S,6S,9R)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5H-ciklohepta[B-]piridin-9-il-4- (2-oxo-2,3-dihidro-1H-imidazo[4,5-B]piridin-1-IL)piperidin-1-karboxilát, hemiszulfát só
JP6062528B2 (ja) 2012-03-29 2017-01-18 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ５−アミノピリミジン誘導体及び望ましくない植物の成長を防除するためのそれらの使用
EP3102564A4 (en) 2014-02-05 2017-10-18 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
KR20200126018A (ko) 2014-03-21 2020-11-05 테바 파마슈티컬스 인터내셔널 게엠베하 칼시토닌 유전자-관련 펩티드에 대한 길항제 항체 및 그의 사용 방법
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
CA3087784A1 (en) 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
BR112020018192A2 (pt) 2019-01-08 2021-08-24 H. Lundbeck A/S Tratamento agudo e tratamento rápido de dor de cabeça com o uso de anticorpos anti-cgrp
AU2021409718A1 (en) 2020-12-22 2023-07-13 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EP1120415B1 (en) 1998-09-30 2003-07-23 Taisho Pharmaceutical Co., Ltd Substituted isoxazolylthiophene compounds
EP1117662A1 (en) * 1998-09-30 2001-07-25 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
CA2487976C (en) * 2002-06-05 2011-07-26 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
ATE466860T1 (de) * 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten

Also Published As

Publication number Publication date
US20040229861A1 (en) 2004-11-18
PE20050020A1 (es) 2005-02-18
JP3967766B2 (ja) 2007-08-29
KR20050121734A (ko) 2005-12-27
US6953790B2 (en) 2005-10-11
US20070225272A1 (en) 2007-09-27
RU2308458C2 (ru) 2007-10-20
AU2004230926B2 (en) 2008-07-17
ATE413400T1 (de) 2008-11-15
TWI314931B (en) 2009-09-21
WO2004092166A3 (en) 2005-01-20
PT1638969E (pt) 2009-01-16
EP2039694A1 (en) 2009-03-25
PL1638969T3 (pl) 2009-04-30
TW200505903A (en) 2005-02-16
US20050256098A1 (en) 2005-11-17
US7772224B2 (en) 2010-08-10
CA2522220A1 (en) 2004-10-28
US7893052B2 (en) 2011-02-22
WO2004092168A1 (en) 2004-10-28
HK1090922A1 (en) 2007-01-05
NO327655B1 (no) 2009-09-07
EP1638969A2 (en) 2006-03-29
NO20055375L (no) 2005-11-14
DE602004017608D1 (de) 2008-12-18
US20100298303A1 (en) 2010-11-25
JO2355B1 (en) 2006-12-12
CN100384843C (zh) 2008-04-30
CL2004000788A1 (es) 2005-02-25
US20080280857A1 (en) 2008-11-13
ECSP056097A (es) 2006-03-01
IS2759B (is) 2011-10-15
EP1638969B1 (en) 2008-11-05
ES2314417T3 (es) 2009-03-16
SI1638969T1 (sl) 2009-02-28
IS8055A (is) 2005-09-29
NZ543357A (en) 2008-08-29
UA82877C2 (en) 2008-05-26
CN1802376A (zh) 2006-07-12
MA27728A1 (fr) 2006-01-02
AR045887A1 (es) 2005-11-16
RU2005135440A (ru) 2006-03-20
EP2039694B1 (en) 2014-03-26
US7235545B2 (en) 2007-06-26
BRPI0409601A (pt) 2006-04-18
WO2004092166A2 (en) 2004-10-28
HRP20080666T3 (en) 2009-01-31
US7534784B2 (en) 2009-05-19
JP2006523697A (ja) 2006-10-19
MXPA05011166A (es) 2005-12-14
DK1638969T3 (da) 2009-01-26
CO5640130A2 (es) 2006-05-31
KR100769030B1 (ko) 2007-10-22
AU2004230926A1 (en) 2004-10-28
CA2522220C (en) 2009-06-23
US20090192139A1 (en) 2009-07-30
US7452903B2 (en) 2008-11-18

Similar Documents

Publication Publication Date Title
CY1108714T1 (el) Ανταγωνιστες υποδοχεα cgrp
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
NO20070606L (no) Inhibitorer av IAP
CY1107915T1 (el) Τρικυκλικες σπιροπιπεριδινες ή σπιροπυρρολιδινες
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
EA200400022A1 (ru) Соединения и способы лечения или предупреждения инфекций flavivirus
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
DK1567193T3 (da) Colonrensemiddelsammensætninger
PA8578601A1 (es) Derivados de 2,2- difenil-benzodioxol
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
NO20063129L (no) Substituerte 6-cykloheksylalkylsubstituerte 2-kinolinoner og 2-kinoksalinoner som poly(ADP-ribose) polymeraseinhibitorer
CY1105301T1 (el) Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
ATE433447T1 (de) Pyrimiidinverbindungen
CY1111246T1 (el) Προληψη και θεραπεια επαγομενης απο φλεγμονη και/ή ανοσοδιαμεσολαβουμενης οστικης απωλειας
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
CY1107149T1 (el) Νεα παραγωγα αμιδινοβενζυλαμινης και χρηση τους ως αναστολεων θρομβινης
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
ATE423122T1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
ATE466860T1 (de) Cgrp-rezeptorantagonisten
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
SE0301446D0 (sv) New Compounds
ECSP066484A (es) Compuestos y metodos para el tratamiento de dislipidemia